Skip to main content

Advertisement

SpringerLink
Log in

Increased vascular inflammation on PET/CT in psoriasis and the effects of biologic treatment: systematic review and meta-analyses

  • Meta-Analysis
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Purpose

This systematic review and meta-analyses evaluate if aortic vascular inflammation is increased in moderate-severe psoriasis compared to a healthy control group and if biologic treatment, compared to placebo, reduces aortic vascular inflammation in moderate-severe psoriasis.

Methods

The systematic review and meta-analyses were reported following PRISMA guidelines. PubMed and Embase databases were searched on June 16, 2021, for the terms ‘psoriasis’, ‘psoriatic arthritis’, and ‘PET/CT’ or ‘vascular inflammation’. Pooled effect sizes were estimated for vascular inflammation outcome measures using a random-effects model with inverse variance weighting.

Results

Four studies, with a total of 224 subjects, were included in the quantitative analysis that studied vascular inflammation in psoriasis compared to healthy controls. Pooled results showed significantly increased vascular inflammation in patients with moderate-severe psoriasis at the entire aorta (composite score) and all aortic segments, except for the infrarenal aorta (p = 0.06). Results of studies assessing treatment effects of different biological agents on vascular inflammation were inconsistent.

Conclusion

Overall, the evidence reviewed indicate that there is an association between psoriasis and aortic vascular inflammation, but there are insufficient evidence for a beneficial effect of biologic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Availability of data and material (data transparency)

Not applicable

Code availability (software application or custom code)

Not applicable

References

  1. Greb JE, Goldminz AM, Elder JT et al (2016) Psoriasis. Nat Rev Dis Prim. https://doi.org/10.1038/nrdp.2016.82

    Article  PubMed  Google Scholar 

  2. Parisi R, Symmons DPM, Griffiths CEM et al (2013) Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 133:377–385. https://doi.org/10.1038/jid.2012.339

    Article  CAS  PubMed  Google Scholar 

  3. Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957–970. https://doi.org/10.1056/NEJMra1505557

    Article  PubMed  Google Scholar 

  4. Ahlehoff O, Gislason GH, Charlot M et al (2011) Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270:147–157. https://doi.org/10.1111/j.1365-2796.2010.02310.x

    Article  CAS  PubMed  Google Scholar 

  5. Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741. https://doi.org/10.1001/jama.296.14.1735

    Article  CAS  PubMed  Google Scholar 

  6. Abuabara K, Azfar RS, Shin DB et al (2010) Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 163:586–592. https://doi.org/10.1111/j.1365-2133.2010.09941.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Davidovici BB, Sattar N, Jörg PC et al (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130:1785–1796. https://doi.org/10.1038/jid.2010.103

    Article  CAS  PubMed  Google Scholar 

  8. Liu Y, Krueger JG, Bowcock AM (2007) Psoriasis: Genetic associations and immune system changes. Genes Immun 8:1–12. https://doi.org/10.1038/sj.gene.6364351

    Article  CAS  PubMed  Google Scholar 

  9. Boehncke WH, Boehncke S, Tobin AM et al (2011) The ‘psoriatic march’: A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20:303–307. https://doi.org/10.1111/j.1600-0625.2011.01261.x

    Article  PubMed  Google Scholar 

  10. Tawakol A, Migrino RQ, Bashian GG et al (2006) In Vivo18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48:1818–1824. https://doi.org/10.1016/j.jacc.2006.05.076

    Article  PubMed  Google Scholar 

  11. Figueroa AL, Abdelbaky A, Truong QA et al (2013) Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 6:1250–1259. https://doi.org/10.1016/j.jcmg.2013.08.006

    Article  PubMed  Google Scholar 

  12. Groenendyk JW, Shukla P, Dey AK et al (2019) Association of aortic vascular uptake of (18)FDG by PET/CT and aortic wall thickness by MRI in psoriasis: a prospective observational study. Eur J Nucl Med Mol Imaging 46:2488–2495. https://doi.org/10.1007/s00259-019-04454-w

    Article  PubMed  PubMed Central  Google Scholar 

  13. Samarasekera EJ, Neilson JM, Warren RB et al (2013) Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133:2340–2346. https://doi.org/10.1038/jid.2013.149

    Article  CAS  PubMed  Google Scholar 

  14. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. https://doi.org/10.1136/bmj.b2700

    Article  PubMed  PubMed Central  Google Scholar 

  15. Bucerius J, Hyafil F, Verberne HJ et al (2016) Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging 43:780–792. https://doi.org/10.1007/s00259-015-3259-3

    Article  PubMed  Google Scholar 

  16. Higgings J, Li T, Deeks J (eds) (2021) Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgings J, Thomas J, Chandler J, et al (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane 2021. www.training.cochrane.org/handbook. Accessed 6 Apr 2021

  17. Rose S, Mehta NN, Sheth NH et al (2013) a Comparison of Vascular Inflammation in Rheumatoid Arthritis, Psoriasis and Healthy Controls By Fdg-Pet/Ct: a Pilot Study. J Am Coll Cardiol 61:E1056. https://doi.org/10.1016/S0735-1097(13)61056-6

    Article  Google Scholar 

  18. Hjuler KFF, Gormsen LCC, Vendelbo MHH et al (2017) Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. Br J Dermatol 176:732–740. https://doi.org/10.1111/bjd.15149

    Article  CAS  PubMed  Google Scholar 

  19. Kim B-S, Lee W-K, Pak K et al (2019) Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: feasibility study using (18)F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol 80:1322–1331. https://doi.org/10.1016/j.jaad.2018.03.011

    Article  CAS  PubMed  Google Scholar 

  20. Goyal A, Dey AK, Chaturvedi A et al (2020) Chronic stress-related neural activity associates with subclinical cardiovascular disease in psoriasis: a prospective cohort study. JACC Cardiovasc Imaging 13:465–477. https://doi.org/10.1016/j.jcmg.2018.08.038

    Article  PubMed  Google Scholar 

  21. Kaur S, Shafiq N, Dogra S et al (2018) 18F-fluorodeoxyglucose positron emission tomography-based evaluation of systemic and vascular inflammation and assessment of the effect of systemic treatment on inflammation in patients with moderate-to-severe psoriasis: A randomized placebo-controlled pi. Indian J Dermatol Venereol Leprol 84:660–666. https://doi.org/10.4103/ijdvl.IJDVL_717_17

    Article  PubMed  Google Scholar 

  22. Youn SW, Kang SY, Kim SA et al (2015) Subclinical systemic and vascular inflammation detected by (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with mild psoriasis. J Dermatol 42:559–566. https://doi.org/10.1111/1346-8138.12859

    Article  PubMed  Google Scholar 

  23. Bissonnette R, Tardif J-C, Harel FFF et al (2013) Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging 6:83–90. https://doi.org/10.1161/CIRCIMAGING.112.975730

    Article  PubMed  Google Scholar 

  24. Bissonnette R, Harel FFF, Krueger JG et al (2017) TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol 137:1638–1645. https://doi.org/10.1016/j.jid.2017.02.977

    Article  CAS  PubMed  Google Scholar 

  25. Mehta NN, Shin DB, Joshi AA et al (2018) Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging 11:e007394. https://doi.org/10.1161/CIRCIMAGING.117.007394

    Article  PubMed  PubMed Central  Google Scholar 

  26. Gelfand JM, Shin DB, Alavi A et al (2020) A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol 140:85-93.e2. https://doi.org/10.1016/j.jid.2019.07.679

    Article  CAS  PubMed  Google Scholar 

  27. Gelfand JM, Shin DB, Duffin KC et al (2020) A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest. https://doi.org/10.1016/j.jid.2020.01.025

    Article  Google Scholar 

  28. Dey AK, Joshi AA, Chaturvedi A et al (2017) Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol 2:1013–1018. https://doi.org/10.1001/jamacardio.2017.1213

    Article  PubMed  Google Scholar 

  29. Eder L, Joshi AA, Dey AK et al (2018) Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol 70:408–416. https://doi.org/10.1002/art.40366

    Article  CAS  PubMed  Google Scholar 

  30. Rivers JP, Powell-Wiley TM, Dey AK et al (2018) Visceral Adiposity in psoriasis is associated with vascular inflammation by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography beyond cardiometabolic disease risk factors in an observational cohort study. JACC Cardiovasc Imaging 11:349–357. https://doi.org/10.1016/j.jcmg.2017.08.014

    Article  PubMed  Google Scholar 

  31. Mehta NN, Yu Y, Saboury B et al (2011) Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 147:1031–1039. https://doi.org/10.1001/archdermatol.2011.119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Elkhawad M, Rudd JHF, Sarov-Blat L et al (2012) Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. JACC Cardiovasc Imaging 5:911–922. https://doi.org/10.1016/j.jcmg.2012.02.016

    Article  PubMed  Google Scholar 

  33. Bural GG, Torigian DA, Chamroonrat W et al (2008) FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 35:562–569. https://doi.org/10.1007/s00259-007-0528-9

    Article  PubMed  Google Scholar 

  34. Rudd JHF, Myers KS, Bansilal S et al (2009) Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2:107–115. https://doi.org/10.1161/CIRCIMAGING.108.811752

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bucerius J, Mani V, Moncrieff C et al (2012) Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol 59:2080–2088. https://doi.org/10.1016/j.jacc.2011.11.069

    Article  PubMed  PubMed Central  Google Scholar 

  36. Noh TS, Moon S-H, Cho YS et al (2013) Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults. J Nucl Med 54:2070–2076. https://doi.org/10.2967/jnumed.113.119602

    Article  CAS  PubMed  Google Scholar 

  37. Mehta NN, Yu Y, Pinnelas R et al (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. https://doi.org/10.1016/j.amjmed.2011.03.028

    Article  PubMed  PubMed Central  Google Scholar 

  38. Reich K (2012) The concept of psoriasis as a systemic inflammation: Implications for disease management. J Eur Acad Dermatology Venereol 26:3–11. https://doi.org/10.1111/j.1468-3083.2011.04410.x

    Article  Google Scholar 

  39. Boehncke WH (2018) Systemic inflammation and cardiovascular comorbidity in psoriasis patients: Causes and consequences. Front Immunol. https://doi.org/10.3389/fimmu.2018.00579

    Article  PubMed  PubMed Central  Google Scholar 

  40. Späh F (2008) Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159:10–17. https://doi.org/10.1111/j.1365-2133.2008.08780.x

    Article  CAS  PubMed  Google Scholar 

  41. Bergheanu SC, Bodde MC, Jukema JW (2017) Pathophysiology and treatment of atherosclerosis: current view and future perspective on lipoprotein modification treatment. Neth Hear J 25:231–242. https://doi.org/10.1007/s12471-017-0959-2

    Article  CAS  Google Scholar 

  42. Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509. https://doi.org/10.1191/026635500701526679

    Article  CAS  PubMed  Google Scholar 

  43. González-Cantero A, Ortega-Quijano D, Álvarez-Díaz N et al (2021) Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials. J Invest Dermatol. https://doi.org/10.1016/j.jid.2021.03.024

    Article  PubMed  Google Scholar 

  44. von Stebut E, Reich K, Thaçi D et al (2019) Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 139:1054–1062. https://doi.org/10.1016/j.jid.2018.10.042

    Article  CAS  Google Scholar 

  45. Wu Y-W, Kao H-L, Huang C-L et al (2012) The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging 39:399–407. https://doi.org/10.1007/s00259-011-1994-7

    Article  CAS  PubMed  Google Scholar 

  46. Kaiser H, Kvist-Hansen A, Krakauer M et al (2021) Statin therapy and vascular inflammation detected by positron emission tomography/computed tomography in patients with psoriasis. Acta Derm Venereol. https://doi.org/10.2340/00015555-3752

    Article  PubMed  Google Scholar 

  47. van der Valk FM, Bernelot Moens SJ, Verweij SL et al (2016) Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. Ann Rheum Dis 75:1848–1851. https://doi.org/10.1136/annrheumdis-2016-209176

    Article  PubMed  Google Scholar 

  48. Reveille JD (2012) Genetics of spondyloarthritis–beyond the MHC. Nat Rev Rheumatol 8:296–304. https://doi.org/10.1038/nrrheum.2012.41

    Article  CAS  PubMed  Google Scholar 

  49. Niccoli Asabella A, Ciccone MM, Cortese F et al (2014) Higher reliability of 18F-FDG target background ratio compared to standardized uptake value in vulnerable carotid plaque detection: a pilot study. Ann Nucl Med 28:571–579. https://doi.org/10.1007/s12149-014-0850-9

    Article  CAS  PubMed  Google Scholar 

  50. Sugawara Y, Zasadny KR, Neuhoff AW et al (1999) Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 213:521–525. https://doi.org/10.1148/radiology.213.2.r99nv37521

    Article  CAS  PubMed  Google Scholar 

  51. Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354. https://doi.org/10.1007/s00259-014-2961-x

    Article  CAS  Google Scholar 

Download references

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

    N. J. Kleinrensink, J. N. Pouw, E. F. A. Leijten & P. M. J. Welsing

  2. Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands

    N. J. Kleinrensink, R. A. P. Takx, B. de Keizer, P. A. de Jong & W. Foppen

  3. Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

    J. N. Pouw & E. F. A. Leijten

Authors
  1. N. J. Kleinrensink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. N. Pouw
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. F. A. Leijten
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. A. P. Takx
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. M. J. Welsing
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. de Keizer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. A. de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. Foppen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NJK: Literature search and review, meta-analysis, writing, editing. JNP: literature review, meta-analysis, writing, editing. EFAL: editing. RAPT: editing. PMJW: meta-analysis, editing. BdK: editing. PAdJ: editing. WF: literature review, Meta-analysis, writing, editing.

Corresponding author

Correspondence to N. J. Kleinrensink.

Ethics declarations

Conflicts of interest

The department of Radiology of the UMC Utrecht receives research support from Philips Healthcare. Prof de Jong provides consultancy to Sanifit and InoZyme. All other authors declare no conflict of interest.

Ethics approval

Not applicable. This article does not contain any studies with human or animal subjects performed by the any of the authors.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 48 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kleinrensink, N.J., Pouw, J.N., Leijten, E.F.A. et al. Increased vascular inflammation on PET/CT in psoriasis and the effects of biologic treatment: systematic review and meta-analyses. Clin Transl Imaging 10, 225–235 (2022). https://doi.org/10.1007/s40336-021-00476-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-021-00476-3

Keywords

Search

Navigation